Sugi Predict

Sugi Predict / Compounds / Actodigin

Actodigin

Actodigin

SCHEMBL122586

C[C@]12CC[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C3=CCOC3=O)CC[C@]12O

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ATP1A1 P05023 12/20 0.74
▸ ATP1B1 P05026 12/20 0.74
▸ ATP1A3 P13637 12/20 0.74
▸ ATP1B2 P14415 12/20 0.74
▸ ATP1A2 P50993 12/20 0.74
▸ ATP1B3 P54709 12/20 0.74
▸ FXYD2 P54710 12/20 0.74
▸ ATP1A4 Q13733 12/20 0.74
▸ PAX8 Q06710 1/20 0.57
▸ LMNA P02545 1/20 0.54
▸ TP53 P04637 1/20 0.54
▸ HBB P68871 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ MAPT P10636 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Actodigin SCHEMBL29358569 1.00 ATP1A1 (0.74) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL12038737 0.86 ATP1A1 (0.57) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL12057554 0.86 ATP1A1 (0.57) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL15101800 0.86 ATP1A1 (0.57) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Desglucouzarin SCHEMBL30615298 0.85 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Digitoxigenin Gentiobioside SCHEMBL1652279 0.81 ATP1A1 (0.92) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Uzarin SCHEMBL702463 0.81 ATP1A1 (0.92) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Digitoxigenin Gentiobioside SCHEMBL702464 0.81 ATP1A1 (0.92) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL31655532 0.81 ATP1A1 (0.91) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL31135096 0.81 ATP1A1 (0.91) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 — — US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
US-20080206161-A1 QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF FOAMIX PHARMACEUTICALS LTD. (IL) 2008-08-28 — — US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
EP-1890679-A2 STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF Foamix Ltd. (IL) 2008-02-27 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
WO-2007012977-A2 STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF FOAMIX LTD (US) 2007-02-01 — — WO claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 — — US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 — — US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 — — US claimed
US-20060018937-A1 Steroid kit and foamable composition and uses thereof FOAMIX LTD. 2006-01-26 — — US claimed
EP-4706683-A2 CHEWABLE FORMULATIONS Elanco Tiergesundheit AG (CH) 2026-03-11 — — EP disclosed
US-20260034059-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES AQUESTIVE THERAPEUTICS, INC. (US) 2026-02-05 — — US disclosed
US-4261971-A ANIONIC POLYMER WHICH IS SOLUBLE OR INSOLUBLE, DEPENDING ON PH AKTIEBOLAGET HASSLE (SE) 1981-04-14 — — US disclosed
EP-0013262-A2 A pharmaceutical preparation comprising a cardiac glycoside with a polymer coating, and a process for preparation thereof Aktiebolaget Hässle (SE) 1980-07-09 — — EP disclosed
EP-0013263-A2 A pharmaceutical preparation comprising a cardiac glycoside in combination with a polymer, and a process for preparation thereof Aktiebolaget Hässle (SE) 1980-07-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080206161-A1 QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF NR5A1, CYP17A1, LIPA ATP1A1 2985/4885ATP1B1 2525/4885ATP1A3 3459/4885
US-20260034059-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES SORD, SLC6A13, CACNA1A ATP1A1 1428/4885ATP1B1 1334/4885ATP1A3 1023/4885
US-20060018937-A1 Steroid kit and foamable composition and uses thereof KIT, GK, HSD17B7 ATP1A1 822/4885ATP1B1 1494/4885ATP1A3 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.